Positive Data on Infinity Pharma Candidate
Zacks.com
The study will evaluate the safety and efficacy of IPI-145 in iNHL patients whose disease is refractory to radioimmunotherapy or to both Roche/Biogen Idec Inc.'s (RHHBY)/(BIIB - Analyst Report) Rituxan (rituximab) and chemotherapy and who have ...
Infinity Reports Updated Phase 1 Data of IPI-145 in Indolent Non-Hodgkin ...Business Wire (press release)
Infinity Reports Preclinical Data at ASH Annual Meeting in Diffuse Large B ...MarketWatch

all 25 news articles »